In recent years, China's new material intermediates and pharmaceutical intermediates industry has been continuously transforming towards greener, higher-end, and smarter production. Many enterprises have deepened collaborations with universities and research institutions, persistently developing new processes and products. While reducing production costs, they have also enhanced product quality, gradually aligning product standards with international benchmarks to meet the requirements of Europe

With increased R&D investment from domestic enterprises, breakthroughs have been achieved in the purity, stability, and large-scale production of new material and pharmaceutical intermediates. More and more domestic intermediate products are being exported overseas, earning consistent praise from international clients for their stable quality and high cost-performance ratio, propelling China's transition from a "major producer of intermediates" to an "industrial powerhouse."

Numerous domestic new material enterprises are strengthening industry-university-research collaboration with universities and R&D institutions, focusing on the development and technological iteration of new processes for novel material intermediates and pharmaceutical intermediates. Through joint efforts, a batch of high-value-added, low-cost, and low-pollution new technologies have achieved industrialization, effectively meeting the demand for high-quality intermediates in downstream pharmaceut

Driven by rapid development in semiconductors, biopharmaceuticals, and high-end manufacturing, the demand for high-end new material intermediates continues to grow. Domestic companies are accelerating their layout in high-barrier intermediate categories, improving supply chain management and quality control systems, gradually breaking dependence on foreign sources, promoting self-sufficiency in key materials, and providing strong support for industrial chain security.

The novel materials intermediates industry continues to strengthen quality control, fully implementing the ISO quality management system, with products strictly benchmarked against European and American pharmacopoeia standards. Enterprises are user-need-oriented, continuously optimizing production and service systems, adhering to innovation-driven and quality-first principles, and striving to build a globally competitive brand for novel materials intermediates.